Timothy Sullivan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Timothy Sullivan has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Gopi Patel
Division of Infectious Diseases Icahn School of Medicine at Mount Sinai New York New York USA
10 shared publicationsShirish Huprikar
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York
10 shared publicationsMeenakshi Rana
Division of Infectious Diseases Department of Medicine Icahn School of Medicine at Mount Sinai New York New York USA
9 shared publicationsDallas Dunn
Division of Infectious Diseases Department of Medicine Icahn School of Medicine at Mount Sinai New York New York USA
7 shared publications- Sarah Taimur
Department of medicine Division of Infectious Diseases Icahn School of Medicine at Mount Sinai New York New York USA
5 shared publications Simon N. Powell
4 shared publications
Latest Publications
- 29 July 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (8) , e70630
Clinical Experience of Oral Serum‐Derived Bovine Immunoglobulin in Solid Organ Transplant Recipients Diagnosed With Norovirus Infection
Background: Norovirus gastroenteritis can cause serious complications in solid organ transplant (SOT) recipients, and no licensed treatment is available. Typical therapy is supportive care; however, some medications may be used off‐label. Serum‐derived bovine immunoglobulin (IG), a medical food product, has been utilized off‐label for norovirus gastroenteritis, although clinical efficacy is uncertain. The objective of this study was to evaluate the outcomes of SOT recipients who received serum‐derived bovine IG for the treatment of norovirus. Methods: Adult SOT recipients, who received serum‐derived bovine IG as treatment for norovirus between January 2020 and December 2024, were evaluated for inclusion. Outcomes evaluated included improvement in the number of bowel movements to less than three per day, presence of more formed bowel movements, presence of acute kidney injury (AKI), initial response rates, and 90‐day relapse‐free rate. Results: 14 SOT recipients were included. Nine patients had a history of prior norovirus gastroenteritis. Reduction to less than three bowel movements per day occurred in 8/14 (57%) patients. Overall, 12/14 (86%) patients experienced clinical improvement after a median of 4.5 days of serum‐derived bovine IG. Of those alive at 90‐day follow‐up, 8 of 10 (80%) did not experience relapsing norovirus infection. Conclusion: Orally administered serum‐derived bovine IG may be a potential option for SOT recipients with chronic norovirus infection. Larger, well‐designed studies are needed to further define its clinical efficacy.
- 29 July 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (8) , e70630
Clinical Experience of Oral Serum‐Derived Bovine Immunoglobulin in Solid Organ Transplant Recipients Diagnosed With Norovirus Infection
Background: Norovirus gastroenteritis can cause serious complications in solid organ transplant (SOT) recipients, and no licensed treatment is available. Typical therapy is supportive care; however, some medications may be used off‐label. Serum‐derived bovine immunoglobulin (IG), a medical food product, has been utilized off‐label for norovirus gastroenteritis, although clinical efficacy is uncertain. The objective of this study was to evaluate the outcomes of SOT recipients who received serum‐derived bovine IG for the treatment of norovirus. Methods: Adult SOT recipients, who received serum‐derived bovine IG as treatment for norovirus between January 2020 and December 2024, were evaluated for inclusion. Outcomes evaluated included improvement in the number of bowel movements to less than three per day, presence of more formed bowel movements, presence of acute kidney injury (AKI), initial response rates, and 90‐day relapse‐free rate. Results: 14 SOT recipients were included. Nine patients had a history of prior norovirus gastroenteritis. Reduction to less than three bowel movements per day occurred in 8/14 (57%) patients. Overall, 12/14 (86%) patients experienced clinical improvement after a median of 4.5 days of serum‐derived bovine IG. Of those alive at 90‐day follow‐up, 8 of 10 (80%) did not experience relapsing norovirus infection. Conclusion: Orally administered serum‐derived bovine IG may be a potential option for SOT recipients with chronic norovirus infection. Larger, well‐designed studies are needed to further define its clinical efficacy.
- 18 January 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (2) , e14439
Invasive Fungal Diseases in Patients With Multiple Myeloma: Experience at a Large, Urban Referral Center
Background: Although infections are a leading cause of morbidity and mortality among patients with multiple myeloma (MM), the epidemiology of invasive fungal disease (IFD) is less well characterized in this population than in other hematologic malignancies. Methods: We conducted a nested 3:1 case‐control study of IFD at a large MM referral center to identify risk factors for IFD in this population. Results: In a cohort of 2960 patients, we identified 32 episodes of IFD among 31 patients between 01/2011 and 06/2019. There was a median of 3.6 years from MM diagnosis to IFD, and patients had a median of four lines of chemotherapy (range 1–12) before IFD. Seventeen (53%) had previous autologous hematopoietic cell transplants. At the time of IFD, 23 (72%) had progressive disease status. Fifteen (47%) and 13 (41%) had severe neutropenia and lymphopenia, respectively, and 18 (56%) had hypogammaglobulinemia. Microbiologic etiologies included Aspergillus ( n = 18), Candida ( n = 6), Cryptococcus ( n = 3), Mucorales ( n = 3), Histoplasma ( n = 1), and undetermined organism ( n = 1). In the case‐control analysis, progressive disease status (OR 1.35, p = 0.02) and neutropenia (OR 17.5, p = 0.02) were significant risk factors for IFD. In addition, ≥3 prior lines of chemotherapy trended toward statistical significance (OR 5.6, p = 0.07). Conclusion: This is the largest detailed description of IFD epidemiology in MM patients and the largest controlled analysis of risk factors in this population. Overall, the risk of IFD was low.
- 18 January 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (2) , e14439
Invasive Fungal Diseases in Patients With Multiple Myeloma: Experience at a Large, Urban Referral Center
Background: Although infections are a leading cause of morbidity and mortality among patients with multiple myeloma (MM), the epidemiology of invasive fungal disease (IFD) is less well characterized in this population than in other hematologic malignancies. Methods: We conducted a nested 3:1 case‐control study of IFD at a large MM referral center to identify risk factors for IFD in this population. Results: In a cohort of 2960 patients, we identified 32 episodes of IFD among 31 patients between 01/2011 and 06/2019. There was a median of 3.6 years from MM diagnosis to IFD, and patients had a median of four lines of chemotherapy (range 1–12) before IFD. Seventeen (53%) had previous autologous hematopoietic cell transplants. At the time of IFD, 23 (72%) had progressive disease status. Fifteen (47%) and 13 (41%) had severe neutropenia and lymphopenia, respectively, and 18 (56%) had hypogammaglobulinemia. Microbiologic etiologies included Aspergillus ( n = 18), Candida ( n = 6), Cryptococcus ( n = 3), Mucorales ( n = 3), Histoplasma ( n = 1), and undetermined organism ( n = 1). In the case‐control analysis, progressive disease status (OR 1.35, p = 0.02) and neutropenia (OR 17.5, p = 0.02) were significant risk factors for IFD. In addition, ≥3 prior lines of chemotherapy trended toward statistical significance (OR 5.6, p = 0.07). Conclusion: This is the largest detailed description of IFD epidemiology in MM patients and the largest controlled analysis of risk factors in this population. Overall, the risk of IFD was low.
- Open Access
- 2 January 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (1) , ofad698
Trypanosoma cruzi Reactivation After Chimeric Antigen Receptor T-Cell Therapy
Https://tidbitapp.io/tidbits/trypanosoma-cruzi-reactivation-post-chimeric-antigen-receptor-t-cell-therapy/update
- 2 January 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (1) , ofad698
Open AccessTrypanosoma cruzi Reactivation After Chimeric Antigen Receptor T-Cell Therapy
Https://tidbitapp.io/tidbits/trypanosoma-cruzi-reactivation-post-chimeric-antigen-receptor-t-cell-therapy/update
- Open Access
- 22 June 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (1) , 7-9
Lessons (Machine) Learned From COVID-19
Since coronavirus disease 2019 (COVID-19) first emerged more than 3 years ago, more than 1200 articles have been written describing “lessons learned” from the pandemic. While these articles may contain valuable insights, reading them all would be impossible. A machine learning clustering analysis was therefore performed to obtain an overview of these publications and to highlight the benefits of using machine learning to analyze the vast and ever-growing COVID-19 literature.
- 22 June 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (1) , 7-9
Open AccessLessons (Machine) Learned From COVID-19
Since coronavirus disease 2019 (COVID-19) first emerged more than 3 years ago, more than 1200 articles have been written describing “lessons learned” from the pandemic. While these articles may contain valuable insights, reading them all would be impossible. A machine learning clustering analysis was therefore performed to obtain an overview of these publications and to highlight the benefits of using machine learning to analyze the vast and ever-growing COVID-19 literature.
- 30 April 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (3) , e13841
Pulmonary nocardiosis in a heart transplant recipient diagnosed with plasma next‐generation sequencing
- 30 April 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (3) , e13841
Pulmonary nocardiosis in a heart transplant recipient diagnosed with plasma next‐generation sequencing
- 17 January 2021
- Published by Wiley in Acta Ophthalmologica
- Vol. 99 (S265)
A rare case of epithelial‐myoepithelial carcinoma arising from pleomorphic adenoma of the lacrimal gland
Purpose: Epithelial‐myoepithelial carcinoma (EMC) is a low‐grade salivary gland tumour which is very rarely reported in the lacrimal gland. Hybrid carcinomas such as EMC, defined by Seifert and Donath (1996),1 comprise two histological subtypes of carcinoma within the same topographic field. Hybrid tumours constitute 2 The diagnosis of EMC is histological, demonstrating a biphasic dual morphology of luminal cuboidal ductal epithelial cells and outer myoepithelial cells with clear cytoplasm.1,2Methods/Results: We describe the case of a 92‐year‐old transgender man that presented with progressively worsening left‐sided headaches, eye pain and with a clinical enlargement of the left lacrimal region. The patient underwent superior‐lateral orbitotomy with excisional biopsy of the left lacrimal gland and was found to have EMC arising from a pleomorphic adenoma, which was subsequently managed with adjuvant rotation therapy.Conclusions: Patient prognostication and optimal management of these tumours provide a challenge for clinicians due to their inherent rarity. We describe the first case of EMC arising within a pleomorphic adenoma in the Australian population.References: 1. Seifert G, Donath K. Hybrid tumours of salivary glands. Definition and classification of five rare cases. European Journal Of Cancer Part B, Oral Oncology 1996; 32B: 251‐259.Li E, Distefano A, Sinard J, Wong A, Pointdujour‐Lim R. Epithelial‐myoepithelial carcinoma presenting as a pseudo veno‐lymphatic malformation. Ophthalmic Plastic And Reconstructive Surgery 2018; 34: e157‐e60.
- 17 January 2021
- Published by Wiley in Acta Ophthalmologica
- Vol. 99 (S265)
A rare case of epithelial‐myoepithelial carcinoma arising from pleomorphic adenoma of the lacrimal gland
Purpose: Epithelial‐myoepithelial carcinoma (EMC) is a low‐grade salivary gland tumour which is very rarely reported in the lacrimal gland. Hybrid carcinomas such as EMC, defined by Seifert and Donath (1996),1 comprise two histological subtypes of carcinoma within the same topographic field. Hybrid tumours constitute 2 The diagnosis of EMC is histological, demonstrating a biphasic dual morphology of luminal cuboidal ductal epithelial cells and outer myoepithelial cells with clear cytoplasm.1,2Methods/Results: We describe the case of a 92‐year‐old transgender man that presented with progressively worsening left‐sided headaches, eye pain and with a clinical enlargement of the left lacrimal region. The patient underwent superior‐lateral orbitotomy with excisional biopsy of the left lacrimal gland and was found to have EMC arising from a pleomorphic adenoma, which was subsequently managed with adjuvant rotation therapy.Conclusions: Patient prognostication and optimal management of these tumours provide a challenge for clinicians due to their inherent rarity. We describe the first case of EMC arising within a pleomorphic adenoma in the Australian population.References: 1. Seifert G, Donath K. Hybrid tumours of salivary glands. Definition and classification of five rare cases. European Journal Of Cancer Part B, Oral Oncology 1996; 32B: 251‐259.Li E, Distefano A, Sinard J, Wong A, Pointdujour‐Lim R. Epithelial‐myoepithelial carcinoma presenting as a pseudo veno‐lymphatic malformation. Ophthalmic Plastic And Reconstructive Surgery 2018; 34: e157‐e60.
- Open Access
- 9 January 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (4) , e14221
Influence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID‐19)
The influence of patient characteristics and immunosuppression management on COVID‐19 outcomes in kidney transplant recipients (KTRs) remains uncertain. We performed a single‐center, retrospective review of all adult KTRs admitted to the hospital with confirmed COVID‐19 between 03/15/2020 and 05/15/2020. Patients were followed from the date of admission up to 1 month following hospital discharge or study conclusion (06/15/2020). Baseline characteristics, laboratory parameters, and immunosuppression were compared between survivors and patients who died to identify predictors of mortality. 38 KTRs with a mean baseline eGFR of 52.5 ml/min/1.73 m2 were hospitalized during the review period. Maintenance immunosuppression included tacrolimus (84.2%), mycophenolate (89.5%), and corticosteroids (81.6%) in the majority of patients. Eleven patients (28.9%) died during the hospitalization. Older age (OR = 2.05; 1.04‐4.04), peak D‐dimer (OR = 1.20; 1.04‐1.39), and peak white blood cell count (OR = 1.11; 1.02‐1.21) were all associated with mortality among KTRs hospitalized for COVID‐19. Increased mortality was also observed among KTRs with concomitant HIV infection (87.5% vs. 36.1%; p < .01). Conversely, immunosuppression intensity and degree of reduction following COVID‐19 diagnosis were not associated with either survival or acute allograft rejection. Our findings potentially support a strategy of individualization of immunosuppression targets based on patient‐specific risk factors, rather than universal immunosuppression reduction for KTRs at risk from COVID‐19.
- 9 January 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (4) , e14221
Open AccessInfluence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID‐19)
The influence of patient characteristics and immunosuppression management on COVID‐19 outcomes in kidney transplant recipients (KTRs) remains uncertain. We performed a single‐center, retrospective review of all adult KTRs admitted to the hospital with confirmed COVID‐19 between 03/15/2020 and 05/15/2020. Patients were followed from the date of admission up to 1 month following hospital discharge or study conclusion (06/15/2020). Baseline characteristics, laboratory parameters, and immunosuppression were compared between survivors and patients who died to identify predictors of mortality. 38 KTRs with a mean baseline eGFR of 52.5 ml/min/1.73 m2 were hospitalized during the review period. Maintenance immunosuppression included tacrolimus (84.2%), mycophenolate (89.5%), and corticosteroids (81.6%) in the majority of patients. Eleven patients (28.9%) died during the hospitalization. Older age (OR = 2.05; 1.04‐4.04), peak D‐dimer (OR = 1.20; 1.04‐1.39), and peak white blood cell count (OR = 1.11; 1.02‐1.21) were all associated with mortality among KTRs hospitalized for COVID‐19. Increased mortality was also observed among KTRs with concomitant HIV infection (87.5% vs. 36.1%; p < .01). Conversely, immunosuppression intensity and degree of reduction following COVID‐19 diagnosis were not associated with either survival or acute allograft rejection. Our findings potentially support a strategy of individualization of immunosuppression targets based on patient‐specific risk factors, rather than universal immunosuppression reduction for KTRs at risk from COVID‐19.
- Open Access
- 12 September 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (12) , e14089
Treatment with convalescent plasma in solid organ transplant recipients with COVID‐19: Experience at large transplant center in New York City
Solid organ transplant (SOT) recipients may be at higher risk for poor outcomes with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Convalescent plasma is an investigational therapy that may benefit immunosuppressed patients by providing passive immunity. Convalescent plasma was administered to hospitalized patients with coronavirus disease‐2019 (COVID‐19) at an academic transplant center in New York City. Eligible patients were hospitalized and required to have positive nasopharyngeal polymerase chain reaction (PCR) diagnosis of SARS‐CoV‐2 infection, be at least 18 years old, and have either dyspnea, blood oxygen saturation ≤ 93% on ambient air, respiratory frequency ≥ 30 breaths/min, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, or lung infiltrates > 50%. Thirteen SOT recipients received convalescent plasma from April 9, 2020, to May 17, 2020. The median time from symptom onset to plasma infusion was 8 days. Eight of 13 patients (62%) had de‐escalating oxygenation support by day 7 post‐convalescent plasma. Nine (69%) patients were discharged, 1 (7%) patients remain hospitalized, and 3 (23%) patients died. This series supports the need for additional studies on convalescent plasma use in SOT recipients with COVID‐19 to better determine efficacy and identify patients who are likely to benefit.
- 12 September 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (12) , e14089
Open AccessTreatment with convalescent plasma in solid organ transplant recipients with COVID‐19: Experience at large transplant center in New York City
Solid organ transplant (SOT) recipients may be at higher risk for poor outcomes with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Convalescent plasma is an investigational therapy that may benefit immunosuppressed patients by providing passive immunity. Convalescent plasma was administered to hospitalized patients with coronavirus disease‐2019 (COVID‐19) at an academic transplant center in New York City. Eligible patients were hospitalized and required to have positive nasopharyngeal polymerase chain reaction (PCR) diagnosis of SARS‐CoV‐2 infection, be at least 18 years old, and have either dyspnea, blood oxygen saturation ≤ 93% on ambient air, respiratory frequency ≥ 30 breaths/min, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, or lung infiltrates > 50%. Thirteen SOT recipients received convalescent plasma from April 9, 2020, to May 17, 2020. The median time from symptom onset to plasma infusion was 8 days. Eight of 13 patients (62%) had de‐escalating oxygenation support by day 7 post‐convalescent plasma. Nine (69%) patients were discharged, 1 (7%) patients remain hospitalized, and 3 (23%) patients died. This series supports the need for additional studies on convalescent plasma use in SOT recipients with COVID‐19 to better determine efficacy and identify patients who are likely to benefit.
- 18 June 2020
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 41 (9) , 1096-1098
Using deep learning and Twitter data to identify outpatient antibiotic misuse
- 18 June 2020
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 41 (9) , 1096-1098
Using deep learning and Twitter data to identify outpatient antibiotic misuse
- 1 June 2020
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 18 (7) , 1409-1411
What Should Gastroenterologists and Patients Know About COVID-19?
- 1 June 2020
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 18 (7) , 1409-1411
What Should Gastroenterologists and Patients Know About COVID-19?